says Fredrik Meurling.
The digital healthcare provider Yazen secures €50 million in a partnership led by the European growth investor Verdane.
08 October 26
The digital healthcare provider Yazen secures €50 million (approximately SEK 500 million) in a partnership led by the European growth investor Verdane.
The investment cements Yazen’s position as an established multinational provider of medical obesity care.
The previous lead investor, Evli Growth Partners (EGP), is also participating in the round.
The capital will be used to scale Yazen's evidence-based care model across Europe.
The investment cements Yazen’s position as an established multinational provider of medical obesity care.
The previous lead investor, Evli Growth Partners (EGP), is also participating in the round.
The capital will be used to scale Yazen's evidence-based care model across Europe.
PRESS RELEASE 2026-10-08
The digital healthcare provider Yazen secures €50 million (approximately SEK 500 million) in a partnership led by the European growth investor Verdane.
The investment cements Yazen’s position as an established multinational provider of medical obesity care. The previous lead investor, Evli Growth Partners (EGP), is also participating in the round. The capital will be used to scale Yazen's evidence-based care model across Europe.
The digital healthcare provider Yazen has secured €50 million (approximately SEK 500 million) in a partnership led by European growth investor Verdane, with participation from previous lead investor Evli Growth Partners (EGP). The investment cements Yazen’s position as an established multinational provider of medical obesity care, and the capital will be used to scale its evidence-based care model across Europe. Yazen specialises in the treatment of obesity as a chronic disease. Headquartered in Sweden and currently operating across eight European countries, Yazen combines modern weight-loss medication with continuous digital care from a multidisciplinary team. Today, over 50,000 patients are actively in treatment via the platform, with over 70,000 patients helped in total and more than 880 tonnes lost. Yazen's team consists of 290 employees, including 210 clinical staff and 115 licensed doctors.
Obesity is a chronic, progressive disease and one of the greatest public health challenges of our time. At the same time, patients testify to widespread stigmatisation and a history of the disease being incorrectly treated as a lack of willpower rather than a biological condition.
Yazen has established an evidence-based care model, currently active in eight countries, that combines modern weight-loss medication with continuous care from a dedicated, multidisciplinary healthcare team consisting of doctors, dietitians, psychologists, and physiotherapists.
International data shows that treatment discontinuation is a major challenge, with 20–50% of patients stopping treatment within 12 months. In contrast, a 2025 Yazen study shows that Yazen’s holistic model with close clinical support yields unprecedented adherence, with 70 percent of patients remaining in treatment after 12 months.
“Obesity is a chronic, progressive disease, not a character flaw. Verdane’s thorough evaluation of the European market confirms what our clinical data already shows: our medical model delivers results that set a new standard for the industry. This partnership provides us with a long-term and strong financial foundation. We can now build an established European healthcare platform that helps hundreds of thousands of patients achieve a lastingly healthier life, while simultaneously reducing the burden on public healthcare,"”
CEO of Yazen
A shared vision for responsible and evidence-based care
Verdane has extensive experience navigating regulated healthcare environments and supporting the scaling of responsible, digitally enabled healthcare platforms. With previous investments in companies such as Medadom, Evondos, Smartbox, and Eterno, it possesses a deep understanding of the healthcare sector. Following a comprehensive review of the European market, Verdane chose to invest in Yazen, largely due to the healthcare provider's strong clinical outcomes, high medical quality and strong patient focus.
“We are deeply impressed by the Yazen team and the strong momentum it is demonstrating. Our analysis made it clear that Yazen stands out as a reliable and scalable leader in medical weight management, where it combines medical excellence with accessibility. We are experienced in building responsible, digital healthcare companies with a strong focus on data privacy and medical
governance, and we look forward to supporting Yazen as a long-term partner as it continues to make a measurable and life-changing difference to individual health,”
governance, and we look forward to supporting Yazen as a long-term partner as it continues to make a measurable and life-changing difference to individual health,”
says Cecilia Nytorp.
Principal at Verdane
“When we first backed Yazen two years ago, we saw a team capable of setting a new standard in medical obesity care. Since then, they have expanded across Europe while maintaining uncompromising clinical standards and a deep commitment to their patients. We are delighted to continue our support alongside Verdane as lead investor. This funding provides the scale to reach more European markets and broaden treatment across cardiometabolic care.
The true measure of Yazen’s success, however, is personal. Recently at an event, an individual approached our team solely to express how Yazen had changed his life — a story mirrored by tens of thousands of patients who have found lasting health through this platform.”
says Mikael Hed.
Chairman of the Board, Yazen, and EGP Growth Partner
The investment of €50 million is concrete proof that Yazen’s patient-focused and integrated care model works and is now ready for broad scaling to improve public health across Europe.
More news
Pionix secures more than 8m € to unify global EV charging
November 2025
Smart Reporting to Acquire Fluency for Imaging — uniting to create JacobianTM and accelerate AI-powered reporting
October 2025
Wellth Raises $36M in Oversubscribed Series C as Health Plans Embrace Daily Care Motivation
September 2025